Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium
Galera Therapeutics, Inc. (GRTX)
Company Research
Source: GlobeNewswire
MALVERN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a late-breaker presentation at the 2020 Multidisciplinary Head and Neck Cancers Symposium, which is taking place February 27-29, 2020, in Scottsdale, Ariz. The presentation includes final data from the two-year tumor outcomes follow up of patients with head and neck cancer treated with Galera’s lead product candidate, avasopasem manganese (GC4419), for severe oral mucositis (SOM) in a Phase 2b clinical trial. Details of the presentation are as follows: Presentation Number: LBA 2 Title: Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer Session: Oral Abstr
Show less
Read more
Impact Snapshot
Event Time:
GRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRTX alerts
High impacting Galera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GRTX
News
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewswire
- Galera Adopts Limited Duration Stockholder Rights Agreement [Yahoo! Finance]Yahoo! Finance
- Galera Adopts Limited Duration Stockholder Rights AgreementGlobeNewswire
- Carisma Therapeutics names Eugene Kennedy as chief medical officer May 02, 2024 8:02 AM ET By: Sinchita Mitra , SA News Editor [Seeking Alpha]Seeking Alpha
GRTX
Sec Filings
- 5/16/24 - Form SC
- 5/16/24 - Form 3
- 5/16/24 - Form SC
- GRTX's page on the SEC website